Clinical Trial Update: NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 study of poziotinib as first-line monotherapy for lung adenocarcinoma (Stage IIIB/Stage IV) was terminated; the update does not report trial results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Drugs mentioned

• Poziotinib (poziotinib)

Snippet

Sponsor: National OncoVenture | Conditions: Adenocarcinoma of Lung Stage IIIB, Adenocarcinoma of Lung Stage IV | Phase 2 | Status: TERMINATED